Abstract
Reactions to insect stings vary from a usual small painful swelling at the site to a large local reaction which may involve an entire limb secondary to a late phase allergic response. These alone do not predict future systemic reactions. Systemic reactions, even mild ones are mostly due to specific IgE responses to venom and may be life-threatening. These should be managed immediately and be followed up for possible specific venom immunotherapy (VIT).
Most stings occur away from emergency facilities thus immediate recognition of the event and proper management is essential. Yellow jackets are the main culprits in the general population followed up by honey bees especially among workers in the industry. Other stinging insects include various wasps, hornets, and in southern climates, fire ants. Africanized bees, because of their aggressive nature are a likely source of stings where they occur.
Epinephrine by intramuscular injection is regarded as the treatment of choice for anaphylactic responses followed up by antihistamines alone or in combination with corticosteroids. Auto-injectors of epinephrine should be prescribed and their use is clearly demonstrated under the supervision of a physician or a trained nurse. There is a 20% incidence of second-phase anaphylactic reactivity, and patients need to be warned and monitored for this development.
Patients having systemic reactions should be referred to an Allergy Specialist for evaluation and, if indicated, specific VIT. VIT is usually limited to 3–5 years in most patients with mild to moderate anaphylactic reactions supported by evidence of specific venom allergy, but long term or even life-long treatment may be considered in those whose reaction was particularly severe especially in a setting where future stings are likely. For persons at risk of sting reactions such as agricultural workers, those working in the bee industry and their family members while undergoing VIT, emergency kits containing epinephrine auto-injectors should be reasonably available.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Moffitt JE, Golden DBK, Reisman RE, Lee R, Nicklas R, et al. Stinging insect hypersensitiv-ity: a practice parameter update. J Allergy Clin Immunol. 2004 Oct; 114: 869–86.
Hoffman DR, Jacobson RS. Allergens in Hymenoptera venom. XII. How much protein in a sting? Ann Allergy 1984; 52: 276–78.
Guralnick MW, Benton AW. Entomological aspects of insect sting allergy. In: Levin MI, Lockey RF, eds. Monograph on insect allergy. 4th ed. Milwaukee, WI: American Academy of Allergy, Asthma and Immunology, 2003: pp. 11–26.
Goddard J. Physician's guide to arthropods of medical importance. 4th ed. Boca Raton, FL.: CRC Press, 2003: p. 4.
Barnard JH. Studies of 400 Hymenoptera sting deaths in the United States. J Allergy Clin Immunol 1973; 52: 259–64.
Day JH, Buckeridge DL, Welsh AC. Risk assessment in determining systemic reactivity to honeybee stings in sting-threatened individuals. J Allergy Clin Immunol 1994; 93: 691–705.
McKenna WR. Africanized honeybees. In: Levin MI, Lockey RF, eds. Monograph on insect allergy. 4th ed. Milwaukee, WI: American Academy of Allergy, Asthma and Immunology, 2003: pp. 27–36.
Hamilton, RG. Diagnosis of Hymenoptera venom sensitivity. Curr Opinion Allergy Immunol 2002; 2: 347–51.
Kemp SF. deShazo RD, Moffitt JE, et al. Expanding habitat of the imported fire ant (Solenopsis invicta): a public health concern. J Allergy Clin Immunol 2000; 105: 683–91.
Kemp SF, deShazo RD, Moffitt JE, Williams DF, Buhner WA 2nd. Expanding habitat of the imported fire ant (Solenopsis invicta): a public health concern. J Allergy Clin Immunol 2000; 105: 683–91.
deShazo RD, Williams DF, Moak ES. Fire ant attacks on residents in health care facilities: a report of two cases. Ann Intern Med 1999; 131: 424–9.
Ellis AK, Day JH. Allergy to insect bites and stings. Allergy 1996; 9(3): 18–22.
Tracy JM, Demain JG, Quinn J.M., et al. The natural history of exposure to the imported fire ant, J Allergy Clin Immunol 1995; 95: 824–828.
Caplan EL, Ford JL, Young PF, Ownby DR. Fire ants represent an important risk for anaphy-laxis among residents of an endemic region. J Allergy Clin Immunol 2003; 111: 1274–7.
Solley GO. Stinging and biting insect allergy: an Australian experience. Ann Allergy Asthma Immunol 2004; 93: 532–37.
Yates AB, Moffitt JE, deShazo RD: Anaphylaxis to arthropod bites and stings. Immunol Allergy Clin North Am 2001; 21: 635–51.
Leveau P. Risk factors for allergy to hymenoptera stings Allerg Immunol (Paris) 1993; 25: 220, 224–6.
Fernandez J, Soriano V, Mayorga L, Mayor M. Natural history of Hymenoptera venom allergy in Eastern Spain. Clin Exp Allergy 2005; 35: 179–85.
Dubois AE. Mastocytosis and Hymenoptera allergy. Curr Opin Allergy Clin Immunol 2004; 4: 291–5.
Golden D. Insect allergy. In: Adkinson NF Jr, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER, eds. Middleton's allergy: principles & practice. 4th ed. Vol. 2. Philadelphia, PA: Mosby, 2003: pp. 1475–86.
Golden DBK. Insect sting allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol 2005; 115: 439–47.
Mauriello PM, Barde SH, Georgitis JW, et al. Natural history of large local reactions from stinging insects. J Allergy Clin Immunol 1984; 74: 494–498.
Ellis AK, Day JH. Diagnosis and management of anaphylaxis. Can Med Assoc J 2003; 169(4): 307–12.
Stark BJ, Sullivan TJ. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol 1986; 78: 76–83.
Ellis AK, Day JH. A prospective evaluation of 103 patients with biphasic anaphlyaxis. J Allergy Clin Immunol 2004; 113: S259 [Abs 935].
Ellis AK, Day JH. Incidence and characteristics of biphasic anaphylaxis: a prospective evaluation of 103 patients. Ann Allergy Asthma Immunol. 2007; 98: 64–9.
Gabriel DP, Rodrigues AG Jr, Barsante RC, dos Santos Silva V, Caramori JT, Martim LC, Barretti P, Balbi AL. Severe acute renal failure after massive attack of Africanized bees. Nephrol Dial Transplant. 2004; 19: 2680.
Daher Ede F, da Silva Junior GB, Bezerra GP, Pontes LB, Martins AM, Guimaraes JA. Acute renal failure after massive honeybee stings. Rev Inst Med Trop Sao Paulo. 2003; 45: 45–50.
Reisman R, Livingston A, Late onset allergic reactions including serum sickness after insect stings. J Allergy Clin Immunol 1989; 84: 331–7.
Moffitt JE. Allergic reactions to insect stings and bites. South Med J 2003; 96: 1073–9.
Chen DM, Lee PT, Chou KJ, Fang HC, Chung HM, Chen DM, Chang LK. Descending aortic thrombosis and cerebral infarction after massive wasp stings. Am J Med. 2004; 116: 567–9.
Boz C, Velioglu S, Ozmenoglu M. Acute disseminated encephalomyelitis after bee sting. Neurol Sci. 2003; 23: 313–5.
Likittanasombut P, Witoonpanich R, Viranuvatti K. Encephalomyeloradiculopathy associated with wasp sting. J Neurol Neurosurg Psychiatr 2003; 74: 134–135.
Gawlik R, Rymarczyk B, Rogala B. A rare case of intravascular coagulation after honey bee sting. J Investig Allergol Clin Immunol. 2004; 14: 250–2.
Sheth HG, Sullivan TJ. Optic neuropathy and orbital inflammatory mass after wasp stings. J R Soc Med 2004; 97: 436–7.
Carr ME. Hand-foot syndrome in a patient with multiple fire ant stings. South Med J. 2004; 97: 707–9.
Kalogeromitros D, Gregoriou S, Papaioannou D, Mousatou V, Makris M, Katsarou-Katsari A. Acquired primary cold contact urticaria after Hymenoptera sting. Clin Exp Dermatol. 2004; 29: 93–5.
Panagariya A, Sharma B, Garg A. Oculopalatal syndrome with ataxia following hymenoptera sting. J Assoc Physicians India 2003; 51: 1007–8.
Lin CC, Chang M Y, Lin JL. Hornet sting induced systemic allergic reaction and large local reaction with bulle formation and rhabdomyolysis. J Toxicol Clin Toxicol 2003; 41: 1009–11.
Kim YO, Yoon SA, Kim KJ, Lee BO, Kim BS, Chang YS, Bang BK. Severe rhabdomyolysis and acute renal failure due to multiple wasp stings. Nephrol Dial Transplant. 2003; 18: 1235
Fisher BA, Antonios TF. Atrial flutter following a wasp sting. J Postgrad Med. 2003; 49: 254–5.
Mauriello PM, Barde SH, Georgitis JW, et al. Natural history of large local reactions from stinging insects. J Allergy Clin Immunol 1984; 74: 494–498.
Freeman TM. Hypersensitivity to Hymenoptera stings. New Engl J Med 2004; 351(19):1978–84.
Chamberlain D. Emergency medical treatment of anaphylactic reactions. Project Team of the Resuscitation Council (UK). J Accid Emerg Med 1999; 16(4): 243–7.
Simons FER, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108(5): 871–3.
Anchor J, Settipane RA. Appropriate use of epinephrine in anaphylaxis. Am J Emerg Med 2004; 22: 488–90.
Shaver KJ, Adams C, Weiss SJ. Acute myocardial infarction after administration of low-dose intravenous epinephrine for anaphylaxis. CJEM. 2006; 8: 289–94.
Lieberman P. The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions. J Allergy Clin Immunol 1990; 86(4 Pt 2): 684–6.
Stark BJ, Sullivan TJ. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol 1986; 78 (1 Pt 1): 76–83.
Ellis AK, Day JH. Biphasic anaphylaxis with unusually late onset second phase: a case report. Can J Allergy Clin Immunol 1997; 2(3): 106–9.
Greenberger PA. Contrast media reactions. J Allergy Clin Immunol 1984; 74: 600–5.
Grouhi M, Alshehri M, Hummel D, Roifman CM. Anaphylaxis and epinephrine auto-injector training: who will teach the teachers? J Allergy Clin Immunol 1999; 104: 190–3.
Gold MS, Sainsbury R. First aid anaphylaxis management in children who were prescribed an epinephrine autoinjector device (Epipen). J Allergy Clin Immunol 2000; 106: 171–6.
DeShazo R, Butcher B, Banks W. Reactions to stings of the imported fire ant. N Engl J Med 1990; 323: 462–6.
Reisman R, Insect stings. N Engl J Med 1994; 331: 523–7.
Valentine M, Schuberth K, Kagey-Sobotka A. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 1990; 323: 1601–3.
Freeman TM, Hylander R, Ortiz A, Martin M, Imported fire ant immunotherapy: effectiveness of whole body extracts. J Allergy Clin Immunol 1992; 90: 210–5.
Tankersley MS, Walker RL, Butler WK, Hagan LL, et al. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol 2002; 109: 556–62.
Freeman TM, Hylander R, Ortiz A, Martin M, Imported fire ant immunotherapy: effectiveness of whole body extracts. J Allergy Clin Immunol 1992; 90: 210–5.
Stafford C. Hypersensitivity to fire ant venom. Ann Allergy 1996; 77: 87–99.
Creticos PS, Franklin Adkinson N Jr, Kagey-Sabotka A, et al. Nasal challenge with ragweed in hay fever patients: effect of immunotherapy. J Clin Invest 1985; 76: 2247–53.
Jutel M, Müller UR, Fricker M, et al. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Allergy 1996; 26: 1112–8.
Bellinghausen I, Metz G, Enk AH, et al. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997; 27: 1131–9.
Jutel M, Pichler WJ, Skrbic D, et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen stimulated T cell cultures. J Immunol 1995; 154: 4178–94.
Akdis CA, Akdis M, Blesken T, et al. Epitope specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996; 98: 1676–83.
Akdis CA, Blaser K. IL-10 induced anergy in peripheral T cell and reactivation by microen-vironmental cytokines: two key steps in specific immunotherapy. FASEB J 1999; 13: 603–9.
Akdis CA, Blesken T, Wymann D, et al. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998; 28: 914–25.
Müller UR, Akdis CA, Fricker M, et al. Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in bee sting allergic patients. J Allergy Clin Immunol 1998; 101: 747–54.
Carballido JM, Carballido-Perrig N, Kägi MK, et al. T cell epitope specificity in human allergic and non-allergic subjects to bee venom phospholipase A2. J Immunol 1993; 150: 3582–91.
Akdis CA, Blesken T, Akdis M, et al. Role of IL-10 in specific immunotherapy. J Clin Invest 1998; 102: 98–106.
Jonuleit H, Schmitt E, Stassen M, et al. Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285–90.
Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998; 160: 1212–18.
Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287–96.
Read S, Mauze S, Asseman CF et al. CD38+CD45RB-low T cells: a population of T cells with immune regulatory activities in vitro. Eur J Immunol 1998; 28: 3435–47.
Read S, Powrie F. CD4(+) regulatory T cells. Curr Opin Immunol 2001; 13: 644.
Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33: 233–41.
Kammerer R, Chvatchko Y, Kettner A, Dufour N, Corradin G, Spertini F. Modulation of T-cell responses to phospholipase A2 and phospholipase A2-derived peptides by conventional Bee venom immunotherapy. J Allergy Clin Immunol 1997; 100: 96–103.
Bernstein DI, Mittman RJ, Kagen SL, et al. Clinical and immunologic studies of rapid immu-notherapy in Hymenoptera sensitive patients. J Allergy Clin Immunol 1989; 84: 951–9.
Eberlein-Konig B, Ullmann S, Thomas P, Przybilla B. Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitisation. Clin Exp Allergy 1995; 25: 704–12.
Stephan V, Kuhr J, Urbanek R. Relevance of basophil histamine release changes during venom immunotherapy. Allergy 1989; 44: 453–9.
Bonifazi F, Jutel M, Biló BM, et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60(12): 1459–70.
Ellis AK, Day JH. Clinical reactivity to insect stings. Curr Opin Allergy Clin Immunol 2005; 5: 349–54.
Mauriello PM, Barde SH, Georgitis JW, Reisman RE. Natural history of large local reactions from stinging insects. J Allergy Clin Immunol 1984; 74: 494–8.
Hepner M, Ownby D, Anderson J. Risk of severe reactions in patients taking beta blocker drugs receiving allergen immunotherapy injections. J Allergy Clin Immunol, 1990; 86: 407–411.
Toogood JH. Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol 1988; 81: 1–5.
Alam MM, Alvarez del Real G, Hsieh FH. Cardiopulmonary resuscitation (CPR) in patients with acute anaphylaxis taking beta-blockers. J Allergy Clin Immunol 2005; 115 (Suppl 2): Abs 160.
Simon P, Potier J, Thebaud HE. Risk factors for acute hypersensitivity reactions in hemodi-alysis. Nephrologie 1996; 17: 163–70.
Hermann K, Ring J. The rennin-angiotensin in patients with repeated anaphylactic reactions during Hymenoptera venom hyposensitization and sting challenge. Int Arch Allergy Immunol 1997; 112: 251–6.
White KM, England RW. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol. 2008; 101(4): 426–30.
Schwartz HJ, Golden DBK, Lockey RF. Venom immunotherapy in the Hymenoptera-allergic pregnant patient. J Allergy Clin Immunol 1990; 85: 709–12.
Müller U, Mosbech H. Position paper. Immunotherapy with Hymenoptera venoms. EAACI. Allergy 1993; 48: 36–46.
Bucher C, Korner P, Wüthrich B. Allergy to bumblebee venom. Curr Opin Allergy Immunol 2001; 1: 361–5.
Stern A, Mullner RG, Wüthrich B. Successful treatment of occupational allergy to bumblebee venom after failure with honeybee venom extract. Allergy 2000; 55: 88–91
Biló BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JNG, EAACI Interest Group on Insect Venom Hypersensitivity. Diagnosis of Hymenoptera venom allergy. Allergy 2005; 60: 1339–49.
Reisman RE, Müller UR, Wypych JI, Lazell MI. Studies of coexisting honeybee and vespid-venom sensitivity. J Allergy Clin Immunol 1984; 73: 246–52.
Straumann F, Bucher C, Wüthrich B. Double sensitization to honeybee and wasp venom: immu-notherapy with one venom or with both venoms? Int Arch Immunol 2000; 123: 268–74.
Lichtenstein LM, Valentine MD, Sobotka AK. A case for venom treatment in anaphylactic sensitivity to Hymenoptera sting. N Engl J Med 1974; 290: 1223–7.
Golden DBK, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980; 92: 620–4.
Yunginger JW, Paull BR, Jones RT, Santrach PJ. Rush venom immunotherapy program for honeybee sting sensitivity. J Allergy Clin Immunol 1979; 63: 340–7.
Laurent J, Smiejan JM, Bloch-Morot E, Herman D. Safety of Hymenoptera venom rush immunotherapy. Allergy 1997; 52: 94–6.
Bernstein AJ, Kagen SI, Bernstein DI. Rapid venom immunotherapy is safe routine in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994; 73: 423–42.
Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993; 23: 226–30.
Golden DBK. Practical considerations in venom immunotherapy. Allergy Asthma Proc 1997; 18: 79–80.
Golden D, Kagey-Sobotka A, Valentine M, Lichtenstein L. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981; 67: 370–4.
Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108: 1027–32.
Bousquet J, Menardo JL, Michel FB. Systemic reactions during maintenance immuno-therapy in honeybee venom. Ann Allergy 1988; 61: 63–8.
Golden DBK, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Prolonged-maintenance interval in Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981; 67: 482–4.
Gadde J, Sobotka A, Valentine M, Lichtenstein L, Golden D. Intervals of six and eight weeks in maintenance venom immunotherapy. Ann Allergy 1985; 54: 348.
Confino-Cohen R, Goldberg A, Mekori YA. Deliberate bee sting challenge of patients receiving maintenance venom immunotherapy at a 3-months interval. J Allergy Clin Immunol 1993; 91: 189–94.
Kochuyt AM, Stevens EAM. Safety and efficacy of a 12-week maintenance interval in patients treated with Hymenoptera venom immunotherapy. Clin Exp Allergy 1994; 24: 35–41
Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299: 157–61.
Müller U, Thurnheer U, Patrizzi R, Spiess J, Hoigne R. Immunotherapy in bee sting hyper-sensitivity. Bee venom versus wholebody extract. Allergy 1979; 34: 369–78.
Brown S, Wiese M, Blackman K, Heddle R. Ant venom immunotherapy: a double blind, placebo-controlled cross-over trial. Lancet 2003; 361: 1001–6.
Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89: 529–35.
Mosbech H, Malling H, Biering I, Böwadt H, Sooborg M, Weeke B, Löwenstein H. Immunotherapy with yellow jacket venom. Allergy 1984; 39: 543–9.
Lockey RF, Turkeltaub PC, Olive ES, Hussard JM, Baird-Warren IA, Buckantz SC. The Hymenoptera venom study. III. Safety of venom immunotherapy. J Allergy Clin Immunol 1990; 86: 775–80.
Mosbech H, Müller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. Allergy 2000; 55: 1005–10.
Berchtold E, Maibach R, Müller U. Reduction of side effects from rush-immunotherapy with honey bee venom by pre-treatment with terfenadine. Clin Exp Allergy 1992; 22: 59–65.
Gillman SA, Cummins LH, Kozak PP, Hoffman DR. Venom immunotherapy: comparison of “rush” vs “conventional” schedules. Ann Allergy 1980; 45: 351–4.
Brehler R, Wolf H, Kutting B, Schnitker J, Luger T. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000; 105: 1231–5.
Brockow K, Kiehn M, Riethu” C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized placebo-controlled trial. J Allergy Clin Immunol 1997; 100: 458–63.
Müller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001; 107: 81–86.
Reimers RE, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000; 55: 484–8.
Przybilla B, Ring J, Galosi A, Geursen RG, Stickl HA. Bee venom immunoglobulin for prophylaxis of anaphylactic reactions during bee venom immunotherapy (rush hyposensiti-zation). Immunol Allergy Pract 1986; 8: 107–11.
Jarisch R. Passive immunotherapy in bee venom allergic patients. Arch Dermatol Res 1981; 270: 230–5.
Quercia O, Rafanelli S, Puccinelli P, Stefanini GF. The safety of cluster immunotherapy with aluminium hydroxide-absorbed honeybee venom extract. J Investig Allergol Clin Immunol 2001; 11: 27–33.
Wyss M, Scheitlin T, Stadler BM, Wüthrich B. Immunotherapy with aluminium hydroxide absorbed insect venom extracts (Alutard SQ): immunologic and clinical results of a prospective study over 3 years. Allergy 1993; 48: 81–86.
Müller U, Rabson A, Bischof M, Lomnitzer R, Dreborg S, Lanner A. A double-blind study comparing monomethoxy polyethylene glycol modified honeybee venom and unmodified honeybee venom for immunotherapy. I. Clinical results. J Allergy Clin Immunol 1987; 80: 252–61.
Müller UR. Recombinant Hymenoptera venom allergens. Allergy 2002; 57: 570–6.
Birnbaum J, Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immuno-therapy (210 min): a safety study and risk factors. Clin Exp Allergy 2003; 33: 58–64.
Fricker M, Helbling A, Schwartz L, Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997; 100: 11–15.
Haeberli G, Bronnimann M, Hunziker T, Müller U. Elevated basal serum tryptase and Hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33: 1216–20.
Oude Elberink JNG, De Monchy JGR, Kors JW, Van Doormaal JJ, Dubois AEJ. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99: 153–4.
Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108: 1027–32.
Oude Elberink JN, Dubois AE. Quality of life in insect venom allergic patients. Curr Opin Allergy Clin Immunol 2003; 3: 287–93.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer
About this chapter
Cite this chapter
Ellis, A.K., Day, J.H. (2009). Insect Sting Allergy in Adults. In: Pawankar, R., Holgate, S.T., Rosenwasser, L.J. (eds) Allergy Frontiers: Clinical Manifestations. Allergy Frontiers, vol 3. Springer, Tokyo. https://doi.org/10.1007/978-4-431-88317-3_28
Download citation
DOI: https://doi.org/10.1007/978-4-431-88317-3_28
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-88316-6
Online ISBN: 978-4-431-88317-3
eBook Packages: MedicineMedicine (R0)